Moreover, SIRT7 may also contribute to the upregulation of PD-L1 in pancreatic cancer, but the supporting evidence remains limited, and the molecular mechanisms by which SIRT7 exerts these immunomodulatory effects in both malignancies are not yet delineated [45,66]. Here, SIRT7 is linked to familial pancreatic carcinoma.